{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:47:18Z","timestamp":1788306438127,"version":"build-2803163510"},"reference-count":90,"publisher":"American Academy of Pediatrics (AAP)","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"abstract":"<jats:p>After a Pompe disease diagnosis is confirmed in infants identified through newborn screening (NBS), when and if to start treatment with enzyme replacement therapy (ERT) with alglucosidase alfa must be determined. In classic infantile-onset Pompe disease, ERT should start as soon as possible. Once started, regular, routine follow-up is necessary to monitor for treatment effects, disease progression, and adverse effects. Decision-making for when or if to start ERT in late-onset Pompe disease (LOPD) is more challenging because patients typically have no measurable signs or symptoms or predictable time of symptom onset at NBS. With LOPD, adequate, ongoing follow-up and assessments for onset or progression of signs and symptoms are important to track disease state and monitor and adjust care before and after treatment is started. Because numerous tests are used to monitor patients at variable frequencies, a standardized approach across centers is lacking. Significant variability in patient assessments may result in missed opportunities for early intervention. Management of Pompe disease requires a comprehensive, multidisciplinary approach with timely disease-specific interventions that target the underlying disease process and symptom-specific manifestations. Regardless of how identified, all patients who have signs or symptoms of the disease require coordinated medical care and follow-up tailored to individual needs throughout their lives. The Pompe Disease Newborn Screening Working Group identifies key considerations before starting and during ERT; summarizes what comprises an indication to start ERT; and provides guidance on how to determine appropriate patient management and monitoring and guide the frequency and type of follow-up assessments for all patients identified through NBS.<\/jats:p>","DOI":"10.1542\/peds.2016-0280e","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T08:36:03Z","timestamp":1498811763000},"page":"S24-S45","source":"Crossref","is-referenced-by-count":61,"title":["Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum"],"prefix":"10.1542","volume":"140","author":[{"given":"David F.","family":"Kronn","sequence":"first","affiliation":[{"name":"Department of Pathology and Pediatrics, New York Medical College, Valhalla, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Day-Salvatore","sequence":"additional","affiliation":[{"name":"Saint Peter\u2019s University Hospital, New Brunswick, New Jersey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuh-Liang","family":"Hwu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Medical Genetics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[{"name":"Manchester Centre for Genomic Medicine, Saint Mary\u2019s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimitoshi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Kumamoto University, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torayuki","family":"Okuyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, National Center for Child Health and Development, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Swoboda","sequence":"additional","affiliation":[{"name":"Center for Human Genetics Research, Massachusetts General Hospital, Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Pompe Disease Newborn Screening Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2017,7,1]]},"reference":[{"key":"2021121007441227700_B1","year":"2014"},{"key":"2021121007441227700_B2","year":"2014"},{"issue":"5","key":"2021121007441227700_B3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline [published correction appears in Genet Med. 2006;8(6):382].","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"issue":"23","key":"2021121007441227700_B4","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1212\/WNL.0b013e31818da93f","article-title":"Management and treatment of glycogenosis type II.","volume":"71","author":"Bembi","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"2021121007441227700_B5","doi-asserted-by":"crossref","first-page":"e67052","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.","volume":"8","author":"Banugaria","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"2021121007441227700_B6","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2008-3667","article-title":"Pompe disease in infants: improving the prognosis by newborn screening and early treatment.","volume":"124","author":"Chien","year":"2009","journal-title":"Pediatrics"},{"issue":"3","key":"2021121007441227700_B7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease.","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr Res"},{"issue":"2","key":"2021121007441227700_B8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"2021121007441227700_B9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.","volume":"149","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"issue":"1","key":"2021121007441227700_B10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nmd.2004.10.009","article-title":"Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.","volume":"15","author":"Klinge","year":"2005","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"2021121007441227700_B11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet Med"},{"issue":"9227","key":"2021121007441227700_B12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","article-title":"Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.","volume":"356","author":"Van den Hout","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"2021121007441227700_B13","doi-asserted-by":"crossref","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"issue":"4","key":"2021121007441227700_B14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe disease: early diagnosis and early treatment make a difference.","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr Neonatol"},{"issue":"6","key":"2021121007441227700_B15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jpeds.2010.11.053","article-title":"Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening.","volume":"158","author":"Chien","year":"2011","journal-title":"J Pediatr"},{"issue":"2","key":"2021121007441227700_B16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe\u2019s disease.","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"N Engl J Med"},{"key":"2021121007441227700_B17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/8904_2014_339","article-title":"Hypertrophic cardiomyopathy in Pompe disease is not limited to the classic infantile-onset phenotype.","volume":"17","author":"Lee","year":"2014","journal-title":"JIMD Rep"},{"issue":"5","key":"2021121007441227700_B18","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","article-title":"Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.","volume":"259","author":"Angelini","year":"2012","journal-title":"J Neurol"},{"issue":"4","key":"2021121007441227700_B19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2008.09.001","article-title":"Improvement with ongoing enzyme replacement therapy in advanced late-onset Pompe disease: a case study.","volume":"95","author":"Case","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2021121007441227700_B20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.","volume":"257","author":"Strothotte","year":"2010","journal-title":"J Neurol"},{"issue":"6","key":"2021121007441227700_B21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nmd.2008.04.009","article-title":"Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease.","volume":"18","author":"van Capelle","year":"2008","journal-title":"Neuromuscul Disord"},{"issue":"15","key":"2021121007441227700_B22","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease.","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"2021121007441227700_B23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clineuro.2010.09.016","article-title":"24-months results in two adults with Pompe disease on enzyme replacement therapy.","volume":"113","author":"Vielhaber","year":"2011","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"2021121007441227700_B24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.20019","article-title":"Enzyme replacement therapy in late-onset Pompe\u2019s disease: a three-year follow-up.","volume":"55","author":"Winkel","year":"2004","journal-title":"Ann Neurol"},{"issue":"23","key":"2021121007441227700_B25","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1212\/WNL.0b013e31818da91e","article-title":"Diagnosis of glycogenosis type II.","volume":"71","author":"Bembi","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"2021121007441227700_B26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/GIM.0b013e31816b64f9","article-title":"Long-term follow-up after diagnosis resulting from newborn screening: statement of the US Secretary of Health and Human Services\u2019 Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children [published correction appears in Genet Med. 2008;10(5):368].","volume":"10","author":"Kemper","year":"2008","journal-title":"Genet Med"},{"key":"2021121007441227700_B27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-7-88","article-title":"Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study.","volume":"7","author":"van der Beek","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2021121007441227700_B28","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1097\/01.gim.0000223891.82390.ad","article-title":"Newborn screening: toward a uniform screening panel and system.","volume":"8","author":"Watson","year":"2006","journal-title":"Genet Med"},{"issue":"5","key":"2021121007441227700_B29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.gim.0000217786.79173.a8","article-title":"Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.","volume":"8","author":"Cook","year":"2006","journal-title":"Genet Med"},{"issue":"6","key":"2021121007441227700_B30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11882-011-0220-9","article-title":"Pulmonary function testing in young children.","volume":"11","author":"Escobar","year":"2011","journal-title":"Curr Allergy Asthma Rep"},{"issue":"5","key":"2021121007441227700_B31","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1378\/chest.10-1423","article-title":"Infant pulmonary function testing: overview of technology and practical considerations\u2013new current procedural terminology codes effective 2010.","volume":"139","author":"Lesnick","year":"2011","journal-title":"Chest"},{"issue":"10","key":"2021121007441227700_B32","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/GIM.0b013e318183722f","article-title":"Arrhythmias in patients receiving enzyme replacement therapy for infantile Pompe disease.","volume":"10","author":"McDowell","year":"2008","journal-title":"Genet Med"},{"issue":"3","key":"2021121007441227700_B33","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1088\/0967-3334\/35\/3\/R59","article-title":"Pulmonary function testing in children and infants.","volume":"35","author":"Vogt","year":"2014","journal-title":"Physiol Meas"},{"key":"2021121007441227700_B34","volume-title":"The Physician\u2019s Guide to Pompe Disease (Glycogen Storage Disease, Type II; Acid Maltase Deficiency)","author":"National Organization for Rare Diseases","year":"2013"},{"key":"2021121007441227700_B35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/8904_2014_366","article-title":"Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset Pompe disease identified by newborn screening.","volume":"19","author":"Chien","year":"2015","journal-title":"JIMD Rep"},{"issue":"4","key":"2021121007441227700_B36","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nmd.2012.12.003","article-title":"Oropharyngeal dysphagia may occur in late-onset Pompe disease, implicating bulbar muscle involvement.","volume":"23","author":"Hobson-Webb","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"2021121007441227700_B37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01.gim.0000204462.42910.b8","article-title":"Diagnostic challenges for Pompe disease: an under-recognized cause of floppy baby syndrome.","volume":"8","author":"Howell","year":"2006","journal-title":"Genet Med"},{"issue":"4","key":"2021121007441227700_B38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00455-009-9252-x","article-title":"Oropharyngeal dysphagia in infants and children with infantile Pompe disease.","volume":"25","author":"Jones","year":"2010","journal-title":"Dysphagia"},{"issue":"1","key":"2021121007441227700_B39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajmg.c.31320","article-title":"Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.","volume":"160C","author":"Young","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"2021121007441227700_B40","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Hirschhorn","year":"2001","edition":"8th ed."},{"issue":"3","key":"2021121007441227700_B41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mus.22329","article-title":"Consensus treatment recommendations for late-onset Pompe disease.","volume":"45","author":"Cupler","year":"2012","journal-title":"Muscle Nerve"},{"issue":"1","key":"2021121007441227700_B42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.c.31324","article-title":"The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.","volume":"160C","author":"Kishnani","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"2021121007441227700_B43","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2007-2222","article-title":"Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program.","volume":"122","author":"Chien","year":"2008","journal-title":"Pediatrics"},{"issue":"4","key":"2021121007441227700_B44","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jpeds.2014.10.068","article-title":"Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth.","volume":"166","author":"Chien","year":"2015","journal-title":"J Pediatr"},{"key":"2021121007441227700_B45","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2015.10.078","article-title":"Very early treatment for infantile-onset Pompe disease contributes to better outcomes.","volume":"169","author":"Yang","year":"2016","journal-title":"J Pediatr"},{"issue":"9","key":"2021121007441227700_B46","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease.","volume":"14","author":"Prater","year":"2012","journal-title":"Genet Med"},{"issue":"1","key":"2021121007441227700_B47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ajmg.a.36197","article-title":"A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment.","volume":"164A","author":"Yang","year":"2014","journal-title":"Am J Med Genet A"},{"issue":"12","key":"2021121007441227700_B48","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease.","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab Invest"},{"issue":"4","key":"2021121007441227700_B49","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.nurt.2008.08.009","article-title":"Therapeutic approaches in glycogen storage disease type II\/Pompe disease.","volume":"5","author":"Schoser","year":"2008","journal-title":"Neurotherapeutics"},{"issue":"4","key":"2021121007441227700_B50","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/GIM.0b013e3181d2900e","article-title":"The angiotensin-converting enzyme insertion\/deletion polymorphism modifies the clinical outcome in patients with Pompe disease.","volume":"12","author":"de Filippi","year":"2010","journal-title":"Genet Med"},{"key":"2021121007441227700_B51","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13023-014-0102-z","article-title":"Genotype-phenotype correlation in Pompe disease, a step forward.","volume":"9","author":"De Filippi","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"2021121007441227700_B52","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again.","volume":"6","author":"Lim","year":"2014","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"2021121007441227700_B53","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ymgme.2010.08.001","article-title":"Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy.","volume":"101","author":"Raben","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"8","key":"2021121007441227700_B54","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease.","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"issue":"11","key":"2021121007441227700_B55","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/gim.2015.6","article-title":"CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy.","volume":"17","author":"Berrier","year":"2015","journal-title":"Genet Med"},{"issue":"1","key":"2021121007441227700_B56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"2","key":"2021121007441227700_B57","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2013.08.010","article-title":"A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.","volume":"111","author":"Wang","year":"2014","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2021121007441227700_B58","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajmg.c.31319","article-title":"Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.","volume":"160C","author":"Bali","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"2021121007441227700_B59","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ymgmr.2015.10.012","article-title":"Clinical laboratory experience of blood CRIM testing in infantile Pompe disease.","volume":"5","author":"Bali","year":"2015","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"2021121007441227700_B60","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ymgme.2015.11.001","article-title":"Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.","volume":"117","author":"Kishnani","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2021121007441227700_B61","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ymgme.2011.08.003","article-title":"Atypical immunologic response in a patient with CRIM-negative Pompe disease.","volume":"104","author":"Abbott","year":"2011","journal-title":"Mol Genet Metab"},{"key":"2021121007441227700_B62","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jpeds.2009.07.006","article-title":"The Brazilian consensus on the management of Pompe disease.","volume":"155","author":"Llerena","year":"2009","journal-title":"J Pediatr"},{"issue":"3","key":"2021121007441227700_B63","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","article-title":"The impact of antibodies in late-onset Pompe disease: a case series and literature review.","volume":"106","author":"Patel","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"2","key":"2021121007441227700_B64","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease.","volume":"38","author":"van Gelder","year":"2015","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"2021121007441227700_B65","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/eci.12.40","article-title":"Immune modulation in Pompe disease treated with enzyme replacement therapy.","volume":"8","author":"Banugaria","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"2021121007441227700_B66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10545-013-9637-8","article-title":"Letter to the Editors: Concerning \u201cCRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy\u201d by Al Khallaf et al.","volume":"37","author":"Prater","year":"2014","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2021121007441227700_B67","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"issue":"1","key":"2021121007441227700_B68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ajmg.c.31316","article-title":"The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.","volume":"160C","author":"Lacan\u00e1","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"2021121007441227700_B69","doi-asserted-by":"crossref","first-page":"15053","DOI":"10.1038\/mtm.2015.53","article-title":"Targeted approaches to induce immune tolerance for Pompe disease therapy.","volume":"3","author":"Doerfler","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"2021121007441227700_B70","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.ymgme.2015.12.315","article-title":"Prophylactic immune modulation in infantile Pompe disease using low-dose methotrexate induction: a safe, inexpensive, widely accessible, and efficacious strategy.","volume":"117","author":"Kazi","year":"2016","journal-title":"Mol Genet Metab"},{"key":"2021121007441227700_B71","unstructured":"The Pompe Registry . Recommended schedule of assessments. Available at: www.pompe.com\/\u223c\/media\/Pompe\/Files\/en\/PDF\/preg_schedule_of_assessments. pdf. Accessed June 2, 2016"},{"issue":"1","key":"2021121007441227700_B72","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","article-title":"Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri.","volume":"166","author":"Hopkins","year":"2015","journal-title":"J Pediatr"},{"issue":"12","key":"2021121007441227700_B73","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/hmg\/3.12.2231","article-title":"Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (\u221213T\u2013&gt;G) mutation in a majority of patients and a novel IVS10 (+1GT\u2013&gt;CT) mutation.","volume":"3","author":"Huie","year":"1994","journal-title":"Hum Mol Genet"},{"issue":"10","key":"2021121007441227700_B74","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/jmg.32.10.836-a","article-title":"Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients.","volume":"32","author":"Kroos","year":"1995","journal-title":"J Med Genet"},{"issue":"10","key":"2021121007441227700_B75","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/ajmg.a.36110","article-title":"Timing of diagnosis of patients with Pompe disease: data from the Pompe Registry.","volume":"161A","author":"Kishnani","year":"2013","journal-title":"Am J Med Genet A"},{"issue":"5","key":"2021121007441227700_B76","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/GIM.0b013e318211a7e1","article-title":"Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals.","volume":"13","author":"Wang","year":"2011","journal-title":"Genet Med"},{"issue":"2","key":"2021121007441227700_B77","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jpeds.2009.03.015","article-title":"Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease.","volume":"155","author":"Chen","year":"2009","journal-title":"J Pediatr"},{"issue":"5","key":"2021121007441227700_B78","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10545-010-9144-0","article-title":"Hearing loss in Pompe disease revisited: results from a study of 24 children.","volume":"33","author":"van Capelle","year":"2010","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"2021121007441227700_B79","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/mus.24437","article-title":"Correlation between quantitative whole-body muscle magnetic resonance imaging and clinical muscle weakness in Pompe disease.","volume":"51","author":"Horvath","year":"2015","journal-title":"Muscle Nerve"},{"issue":"9","key":"2021121007441227700_B80","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1469-8749.2003.tb00966.x","article-title":"Pompe disease and physical disability.","volume":"45","author":"Haley","year":"2003","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"2021121007441227700_B81","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1067\/mpd.2001.117581","article-title":"Validity of the test of infant motor performance for discriminating among infants with varying risk for poor motor outcome.","volume":"139","author":"Campbell","year":"2001","journal-title":"J Pediatr"},{"issue":"7","key":"2021121007441227700_B82","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/ptj\/75.7.585","article-title":"Construct validity of the test of infant motor performance.","volume":"75","author":"Campbell","year":"1995","journal-title":"Phys Ther"},{"issue":"1","key":"2021121007441227700_B83","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/PEP.0b013e31815f66a6","article-title":"Validity of the TIMPSI for estimating concurrent performance on the test of infant motor performance.","volume":"20","author":"Campbell","year":"2008","journal-title":"Pediatr Phys Ther"},{"issue":"3","key":"2021121007441227700_B84","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability.","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"2021121007441227700_B85","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1212\/WNL.52.4.851","article-title":"A diagnostic protocol for adult-onset glycogen storage disease type II.","volume":"52","author":"Ausems","year":"1999","journal-title":"Neurology"},{"key":"2021121007441227700_B86","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/8904_2013_250","article-title":"Successful desensitisation in a patient with CRIM-positive infantile-onset Pompe disease.","volume":"12","author":"Baruteau","year":"2014","journal-title":"JIMD Rep"},{"issue":"4","key":"2021121007441227700_B87","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ymgme.2011.04.009","article-title":"Expanding the clinical spectrum of late-onset Pompe disease: dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered.","volume":"103","author":"El-Gharbawy","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2021121007441227700_B88","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.nmd.2014.12.004","article-title":"Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.","volume":"25","author":"Case","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"2021121007441227700_B89","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNO.0b013e3181ce162a","article-title":"Improvement of bliateral ptosis on higher doses enzyme replacement therapy in Pompe disease.","volume":"30","author":"Yanovitch","year":"2010","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"2021121007441227700_B90","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajmg.c.31321","article-title":"Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.","volume":"160C","author":"Case","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/140\/Supplement_1\/S24\/1142812\/peds_20160280e.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/140\/Supplement_1\/S24\/1142812\/peds_20160280e.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T03:54:25Z","timestamp":1719287665000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/140\/Supplement_1\/S24\/179262\/Management-of-Confirmed-Newborn-Screened-Patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,1]]},"references-count":90,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2017,7,1]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2016-0280e","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,1]]}}}